Business Context and Reporting Period
Company: MaxCyte, Inc. (MXCT)
Filing Type: Form 8-K (Current Report)
Date of Report: June 10, 2026
Reporting Period: The filing addresses events occurring between March 16, 2026, and June 10, 2026, specifically regarding Nasdaq listing compliance.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on regulatory compliance status regarding stock price.
Material Changes
- Regulatory Status Change: The Company previously received notice on March 16, 2026, of non-compliance with Nasdaq Listing Rule 5450(a)(1) due to a closing bid price below $1.00 for 30 consecutive trading days.
- Resolution: On June 10, 2026, Nasdaq notified the Company that it regained compliance. The closing bid price was at or above $1.00 for the 10 consecutive business days from May 27, 2026, to June 9, 2026.
- Outcome: The delisting matter is now closed.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms the restoration of listing compliance based on recent stock price performance. No forward-looking guidance, strategic outlook, or new risk factors were disclosed in this specific report.
Unusual Items: None reported beyond the resolution of the prior delisting notice.
Investor Verification Checklist
- Verify the current trading price of MXCT to ensure it remains above the $1.00 threshold to maintain compliance.
- Review the March 20, 2026, Form 8-K for details on the initial non-compliance notice and any proposed cure plans.
- Monitor upcoming quarterly reports (10-Q) for financial performance data, as this 8-K contains no financial metrics.